Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19

Int J Tuberc Lung Dis. 2021 Sep 1;25(9):772-775. doi: 10.5588/ijtld.21.0340.

Authors

E Mohr-Holland¹, D Hacking², J Daniels², V Scott³, V Mudaly⁴, J Furin⁵, C Pfaff², A Reuter²

Affiliations

¹ Médecins Sans Frontières (MSF), Khayelitsha, South Africa, MSF Southern Africa Medical Unit, Cape Town, South Africa.
² Médecins Sans Frontières (MSF), Khayelitsha, South Africa.
³ City of Cape Town Department of Health, Eastern Area, Cape Town, South Africa.
⁴ Provincial Government of the Western Cape, Cape Town, South Africa.
⁵ Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Letter

MeSH terms

Antibiotics, Antitubercular* / therapeutic use
COVID-19*
Humans
Mycobacterium tuberculosis*
Rifampin
SARS-CoV-2
Tuberculosis, Multidrug-Resistant* / diagnosis
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antibiotics, Antitubercular
Rifampin